Q-omics provides the consensus-scored MIR367 profile across patient tissues and cancer cell-line models. MIR367 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, MIR367 is differentially expressed in 3, with the highest sampling consensus in PAAD. Additionally, MIR367 RNA expression shows 7,712 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight OV, PAAD, and TGCT as cancer lineages where MIR367 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR367 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR367 survival associations across molecular data types. MIR367 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR367 RNA expression–survival associations across cancer types. High MIR367 expression shows unfavorable associations in OV, BLCA, ACC, UVM and LUAD, but favorable associations in COAD. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for MIR367 RNA expression.
This table summarizes MIR367 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR367. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR367 shows lower tumor expression in PAAD and higher tumor expression in BRCA and THCA. The PAAD box plot shows higher MIR367 RNA expression in normal versus tumor tissue (log2 FC = −1.020, t-test p = .004).
This table shows molecular features associated with MIR367 in patient tissues and cancer cell lines. In patient samples, MIR367 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
